Typhoid fever & vaccine development: A partially answered question

Indian Journal of Medical Research

Volumn 135, Issue 2, 2012, Pages 161-169

  Marathe, Sandhya A ^a   Lahiri, Amit ^a   Negi, Vidya Devi ^a   Chakravortty, Dipshikha ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

DNA vaccine; Immunity; Salmonella; Typhoid fever; Vaccination

Indexed keywords

AMPICILLIN; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CKS 362; DNA VACCINE; INACTIVATED VACCINE; LIVE VACCINE; OFLOXACIN; PEFLOXACIN; SALMONELLOSIS VACCINE; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; MEDICAL LITERATURE; NONHUMAN; SALMONELLA; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SALMONELLOSIS; TYPHOID FEVER;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE; HUMANS; POLYSACCHARIDES, BACTERIAL; SALMONELLA INFECTIONS; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED; VACCINES, DNA;

EID: 84859078057     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. World Health Organisation. Diarrhoeal diseases. Geneva: WHO; 2009.
2. Popoff MY, Bockemühl J, Gheesling LL. Supplement 2002 (no. 46) to the Kauffmann-White scheme. Res Microbiol 2004; 155: 568-70.
3. Baumler AJ, Tsolis RM, Ficht TA, Adams LG. Evolution of host adaptation in Salmonella enterica. Infect Immun 1998; 66: 4579-87.
4. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32: 263-9.
5. Black RE, Cisneros L, Levine MM, Banfi A, Lobos H, Rodriguez H. Case-control study to identify risk factors for paediatric endemic typhoid fever in Santiago, Chile. Bull World Health Organ 1985; 63: 899-904.
6. Luby SP, Faizan MK, Fisher-Hoch SP, Syed A, Mintz ED, Bhutta ZA, et al. Risk factors for typhoid fever in an endemic setting, Karachi, Pakistan. Epidemiol Infect 1998; 120: 129-38.
7. Nagarajan AG, Karnam G, Lahiri A, Allam US, Chakravortty D. Reliable means of diagnosis and serovar determination of blood-borne Salmonella strains: quick PCR amplification of unique genomic loci by novel primer sets. J Clin Microbiol 2009; 47: 2435-41.
8. Prouty AM, Van Velkinburgh JC, Gunn JS. Salmonella enterica serovar Typhimurium resistance to bile: identification and characterization of the tolQRA cluster. J Bacteriol 2002; 184: 1270-6.
9. Prouty AM, Schwesinger WH, Gunn JS. Biofilm formation and interaction with the surfaces of gallstones by Salmonella spp. Infect Immun 2002; 70: 2640-9.
10. Woodward TE, Smadel JE, Ley HL Jr, Green R, Mankikar DS. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med 1948; 29: 131-4.
11. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol 1996; 44: 317-9.
12. Kumar S, Rizvi M, Berry N. Rising prevalence of enteric fever due to multidrug-resistant Salmonella: an epidemiological study. J Med Microbiol 2008; 57: 1247-50.
13. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal Salmonellae. Curr Opin Infect Dis 2008; 21: 531-8.
14. Akinyemi KO, Smith SI, Oyefolu AO, Coker AO. Multidrug resistance in Salmonella enterica serovar Typhi isolated from patients with typhoid fever complications in Lagos, Nigeria. Public Health 2005; 119: 321-7.
15. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT, et al. Antimicrobial drug resistance of Salmonella enterica serovar Typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2007; 51: 4315-23.
16. Helms M, Ethelberg S, Molbak K. International Salmonella Typhimurium DT104 infections, 1992-2001. Emerg Infect Dis 2005; 11: 859-67.
17. Poppe C, Smart N, Khakhria R, Johnson W, Spika J, Prescott J. Salmonella Typhimurium DT104: a virulent and drug-resistant pathogen. Can Vet J 1998; 39: 559-65.
18. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002; 347: 1770-82.
19. Mulvey MR, Boyd DA, Olson AB, Doublet B, Cloeckaert A. The genetics of Salmonella genomic island 1. Microbes Infect 2006; 8: 1915-22.
20. Ribot EM, Wierzba RK, Angulo FJ, Barrett TJ. Salmonella enterica serotype Typhimurium DT104 isolated from humans, United States, 1985, 1990, and 1995. Emerg Infect Dis 2002; 8: 387-91.
21. Groisman EA, Mouslim C. Sensing by bacterial regulatory systems in host and non-host environments. Nat Rev Microbiol 2006; 4: 705-9.
22. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-8.
23. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-92.
24. Chakravortty D, Hansen-Wester I, Hensel M. Salmonella pathogenicity island 2 mediates protection of intracellular Salmonella from reactive nitrogen intermediates. J Exp Med 2002; 195: 1155-66.
25. Tobar JA, Carreno LJ, Bueno SM, Gonzalez PA, Mora JE, Quezada SA, et al. Virulent Salmonella enterica serovar Typhimurium evades adaptive immunity by preventing dendritic cells from activating T cells. Infect Immun 2006; 74: 6438-48.
26. Bueno SM, Gonzalez PA, Schwebach JR, Kalergis AM. T cell immunity evasion by virulent Salmonella enterica. Immunol Lett 2007; 111: 14-20.
27. Groisman EA. The pleiotropic two-component regulatory system PhoP-PhoQ. J Bacteriol 2001; 183: 1835-42.
28. Roland KL, Martin LE, Esther CR, Spitznagel JK. Spontaneous pmrA mutants of Salmonella Typhimurium LT2 define a new two-component regulatory system with a possible role in virulence. J Bacteriol 1993; 175: 4154-64.
29. Shafer WM, Casey SG, Spitznagel JK. Lipid A and resistance of Salmonella Typhimurium to antimicrobial granule proteins of human neutrophil granulocytes. Infect Immun 1984; 43: 834-8.
30. Merighi M, Ellermeier CD, Slauch JM, Gunn JS. Resolvase-in vivo expression technology analysis of the Salmonella enterica serovar Typhimurium PhoP and PmrA regulons in BALB/c mice. J Bacteriol 2005; 187: 7407-16.
31. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82: 346-53.
32. World Health Organisation. Public health response to biological and chemical weapons. Geneva: WHO; 2004.
33. Typhoid vaccines. Wkly Epidemiol Rec 2000; 75: 257-64.
34. Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008; 83: 49-58.
35. Garmory HS, Griffin KF, Leary SE, Perkins SD, Brown KA, Titball RW. The effect of recombinant plasmids on in vivo colonisation of Salmonella enterica serovar Typhimurium strains is not reflected by in vitro cellular invasion assays. Vaccine 2002; 20: 3239-43.
36. Wong KH, Feeley JC, Northrup RS, Forlines ME. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect Immun 1974; 9: 348-53.
37. Wong KH, Feeley JC. Isolation of Vi antigen and a simple method for its measurement. Appl Microbiol 1972; 24: 628-33.
38. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11 (Suppl 3): S552-67.
39. Garmory HS, Brown KA, Titball RW. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002; 26: 339-53.
40. Felix A, Krikorian KS, Reitler R. The Occurrence of typhoid bacilli containing Vi antigen in cases of typhoid fever and of Vi antibody in their sera. J Hyg 1935; 35: 421-7.
41. Felix A. Detection of chronic typhoid carriers by agglutination tests. Lancet 1938; 232: 738-41.
42. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella Typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14: 435-8.
43. Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella Typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 1999; 18: 609-20.
44. Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001; 79: 625-31.
45. Saha MR, Ramamurthy T, Dutta P, Mitra U. Emergence of Salmonella Typhi Vi antigen-negative strains in an epidemic of multidrug-resistant typhoid fever cases in Calcutta, India. Natl Med J India 2000; 13: 164.
46. Mehta G, Arya SC. Capsular Vi polysaccharide antigen in Salmonella enterica serovar Typhi isolates. J Clin Microbiol 2002; 40: 1127-8.
47. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008; 26: 6305-16.
48. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ 1994; 72: 957-71.
49. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella Typhi live oral vaccine. Vaccine 1999; 17 (Suppl 2): S22-7.
50. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar Paratyphi B. Clin Infect Dis 2007; 45 (Suppl 1): S24-8.
51. Stocker BA, Hoiseth SK, Smith BP. Aromatic-dependent Salmonella sp. as live vaccine in mice and calves. Dev Biol Stand 1983; 53: 47-54.
52. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella Typhimurium are non-virulent and effective as live vaccines. Nature 1981; 291: 238-9.
53. Levine MM, Herrington D, Murphy JR, Morris JG, Losonsky G, Tall B, et al. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella Typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest 1987; 79: 888-902.
54. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically defined double aro mutants of Salmonella Typhi. Vaccine 1991; 9: 810-6.
55. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, et al. Safety of live oral Salmonella Typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 1997; 65: 452-6.
56. Tacket CO, Hone DM, Curtiss R, 3rd, Kelly SM, Losonsky G, Guers L, et al. Comparison of the safety and immunogenicity of ΔaroC, ΔaroD and Δ cya Δ crp Salmonella Typhi strains in adult volunteers. Infect Immun 1992; 60: 536-41.
57. Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella Typhi vaccine strain in human volunteers. Vaccine 1996; 14: 19-24.
58. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella Typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173: 1408-14.
59. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005; 192: 360-6.
60. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect Immun 2000; 68: 4647-52.
61. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007; 45 (Suppl 1): S20-3.
62. Negi VD, Singhamahapatra S, Chakravortty D. Salmonella enterica serovar Typhimurium strain lacking pmrG-HM-D provides excellent protection against salmonellosis in murine typhoid model. Vaccine 2007; 25: 5315-23.
63. Lankowski AJ, Hohmann EL. Killed but metabolically active Salmonella Typhimurium: application of a new technology to an old vector. J Infect Dis 2007; 195: 1203-11.
64. Harada H, Nishikawa F, Higashi N, Kita E. Development of a mucosal complex vaccine against oral Salmonella infection in mice. Microbiol Immunol 2002; 46: 891-905.
65. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al. Typhoid fever in children aged less than 5 years. Lancet 1999; 354: 734-7.
66. Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T, et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001; 20: 521-4.
67. Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000; 62: 644-8.
68. Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005; 11: 326-9.
69. Micoli F, Rondini S, Pisoni I, Proietti D, Berti F, Costantino P, et al. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 2011; 29: 712-20.
70. Rollenhagen C, Sorensen M, Rizos K, Hurvitz R, Bumann D. Antigen selection based on expression levels during infection facilitates vaccine development for an intracellular pathogen. Proc Natl Acad Sci USA 2004; 101: 8739-44.
71. Tran TH, Nguyen TD, Nguyen TT, Ninh TT, Tran NB, Nguyen VM, et al. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One 2010; 5: e11778.
72. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000; 68: 1196-201.
73. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344: 1263-9.
74. Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM. Evaluation in volunteers of a candidate live oral attenuated Salmonella Typhi vector vaccine. J Clin Invest 1992; 90: 412-20.
75. Azze RF, Rodriguez JC, Iniesta MG, Marchena XR, Alfonso VM, Padron FT. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers. Vaccine 2003; 21: 2758-60.